Idioma:

Radiotherapy followed by high dose busulfan and thiotepa : A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas

BOUFFET, E ; RAQUIN, M ; DOZ, F ; GENTET, J.-C ; RODARY, C ; DEMEOCQ, F ; CHASTAGNER, P ; LUTZ, P ; HARTMANN, O ; KALIFA, C

Cancer, 2000-02, Vol.88 (3), p.685-692 [Periódico revisado por pares]

New York, NY: Wiley-Liss

Texto completo disponível

Citações Citado por

Enviar para

Título:
Radiotherapy followed by high dose busulfan and thiotepa : A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas
Autor: BOUFFET, E ; RAQUIN, M ; DOZ, F ; GENTET, J.-C ; RODARY, C ; DEMEOCQ, F ; CHASTAGNER, P ; LUTZ, P ; HARTMANN, O ; KALIFA, C
Assuntos: Adolescent ; Antineoplastic agents ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Agents, Alkylating - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biopsy ; Bone Marrow Transplantation ; Brain Stem Neoplasms - drug therapy ; Brain Stem Neoplasms - radiotherapy ; Busulfan - administration & dosage ; Busulfan - adverse effects ; Cause of Death ; Chemotherapy ; Chemotherapy, Adjuvant ; Child ; Child, Preschool ; Combined Modality Therapy ; Disease Progression ; Feasibility Studies ; Female ; Glioma - drug therapy ; Glioma - radiotherapy ; Humans ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Pilot Projects ; Prospective Studies ; Stereotaxic Techniques ; Survival Rate ; Thiotepa - administration & dosage ; Thiotepa - adverse effects ; Transplantation, Autologous ; Treatment Outcome
É parte de: Cancer, 2000-02, Vol.88 (3), p.685-692
Descrição: The role of high dose chemotherapy (HDC) in patients with pediatric brain tumors currently is ill-defined. The purpose of this pilot study was to assess the feasibility and the benefit of HDC after radiotherapy in a group of children with newly diagnosed diffuse pontine gliomas. Patients eligible for study were ages 3-18 years with diffuse intrinsic tumors arising in the pons, who were not treated previously with radiotherapy or chemotherapy. Histologic confirmation was not mandatory, provided clinical findings and magnetic resonance imaging were typical. Patients were given focal radiotherapy followed 2-3 months later by HDC. Busulfan (150 mg/m(2) on Days 8, 7, 6, and 5) and thiotepa (300 mg/m(2) on Days 4, 3, and 2) were administered prior to autologous bone marrow transplantation. Survival was the endpoint, and the statistical procedure was based on sequential subgroup analysis. Thirty-six patients were entered on to the study, 12 of whom underwent stereotactic biopsy or open surgery at the time of diagnosis. One patient eventually was excluded due to inappropriate eligibility criteria. All 35 eligible patients received irradiation. Early progression (9 patients) and parental refusal (2 patients) precluded the use of HDC in 11 patients. Three patients died of HDC-related complications. All 21 patients who survived HDC eventually died of disease progression. The median survival time was 10 months for the study group. The median survival time in the subgroup of patients who received HDC was 10 months (range, 3-26 months). Statistical analysis did not suggest any evidence of survival benefit. For patients with diffuse pontine gliomas, survival using this aggressive treatment modality does not appear to be any better than that reported for conventional radiotherapy.
Editor: New York, NY: Wiley-Liss
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Radiotherapy followed by high dose busulfan and thiotepa : A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas

BOUFFET, E ; RAQUIN, M ; DOZ, F ; GENTET, J.-C ; RODARY, C ; DEMEOCQ, F ; CHASTAGNER, P ; LUTZ, P ; HARTMANN, O ; KALIFA, C

New York, NY: Wiley-Liss

Buscando em bases de dados remotas. Favor aguardar.